Lungs News and Research

RSS

SPARC protein acts much like ibuprofen to heal tissues inflamed by tumors

Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation - most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.

19 Jan 2013

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.

18 Jan 2013

Medications often prescribed for PAH could affect heart health of treated patients

A research team with the Faculty of Medicine & Dentistry at the University of Alberta reported findings that significantly improve understanding of how widely used drugs in Pulmonary Arterial Hypertension (PAH) affect the heart health of treated patients.

18 Jan 2013

mTorc1 promotes growth of inflammation-associated colon and gastric cancers

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a new treatment for these diseases.

18 Jan 2013

Degree of emphysema predicts mortality in ever-smokers with or without COPD

Severity of emphysema, as measured by computed tomography (CT), is a strong independent predictor of all-cause, cardiovascular, and respiratory mortality in ever-smokers with or without chronic obstructive pulmonary disease (COPD), according to a study from researchers in Norway. In patients with severe emphysema, airway wall thickness is also associated with mortality from respiratory causes.

18 Jan 2013

RSAS honors Feinstein Institute scientist with Crafoord Prize for genetic research on arthritis

The Royal Swedish Academy of Sciences announced today that Peter K. Gregersen , MD, a scientist at The Feinstein Institute for Medical Research, will receive the prestigious Crafoord Prize for his genetic research in the area rheumatoid arthritis.

18 Jan 2013

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

The U.S. Food and Drug Administration today approved Octaplas, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels.

18 Jan 2013

Report: Cancer death rates decline 20% from its peak in 1991

As of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately 1.2 million deaths from cancer, 152,900 of these in 2009 alone. These figures come from the American Cancer Society's annual Cancer Statistics report, one of the most widely-cited medical publications in the world.

17 Jan 2013

Palliative planning reduces out-of-hours hospital admissions

Being able to access an electronic palliative care summary for patients with cancer can help doctors make decisions during out-of-hours care and reduce the chances of unplanned hospital admissions, show UK study results.

17 Jan 2013

Quarter of incident lung cancer slow growing or indolent

A quarter of incident lung cancers are slow growing or indolent, and may be overdiagnosed, suggest results from sequential low-dose computed tomography screening.

17 Jan 2013

FDA clears Sanovas’ Vas Zeppelin Smart Catheter to treat chronic pulmonary diseases, lung cancer

Sanovas Inc., a life science technology company developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that it has filed with the U.S. Food and Drug Administration for clearance of the company's Vas Zeppelin Smart Catheter for the treatment of chronic pulmonary diseases and lung cancer.

17 Jan 2013

AeriSeal System may provide relief for patients with emphysema

Those who have emphysema may soon be able to breathe a sigh of relief. That's because alternative ways to treat advanced cases of the condition are being developed.

17 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.

17 Jan 2013

Patients with COPD more likely to develop serious bacterial infections

It is well known that COPD patients run a higher risk of contracting respiratory infections. However, a new thesis from Lund University in Sweden shows that they are also at higher risk of other bacterial infections, such as tuberculosis (TB) and pneumococcal and staphylococcal infections that can cause serious illness.

16 Jan 2013

Study: Patients with EGFR exon 20 insertions need targeted therapies

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

16 Jan 2013

Link between infections and venous thromboembolism in surgical patients

Despite receiving blood thinners and other clot prevention treatment, some patients still develop potentially lethal blood clots in the first month after their operations anyway, especially if they developed a surgical-site infection while in the hospital, according to results of a study at Johns Hopkins.

16 Jan 2013

TSC22D4 gene plays a key role in the onset of cachexia

Cachexia or wasting is a condition affecting up to 70 percent of cancer patients, depending on the type of cancer. It is characterized by a dramatic loss of body weight that is independent of food intake. Cachexia is seen particularly often and most pronounced in patients suffering from cancers of the digestive tract and the lungs.

16 Jan 2013

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Increased NEK2 gene expression linked to increased drug resistance, faster cancer growth, and poorer patient outcome - The finding may improved diagnostic and prognostic tools for cancer care and could lead to improved cancer therapies

16 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013